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ABSTRACT 
In the absence of hypertension, hypertrophic cardiomyopathy is the most common cause of left ventricular hyper-
trophy (LVH). However, it has been reported that up to 3% of males with unexplained LVH have Fabry disease, 
an X-linked disorder of glycophospholipid metabolism that is due to a deficiency in the lysosomal enzyme α-
galactosidase A (α-Gal A). A 44-year-old man was admitted to our hospital with palpitations. He had a history 
of chronic renal failure diagnosed at age 33 followed by kidney transplantation performed at our institution 2 years 
later, as well as long-standing hypohidrosis. His medications included prednisolone (5 mg daily), mycophenolate 
mofetil (1,000 mg, bid), and cyclosporine (150 mg, bid). On hospital day two, an echocardiogram demonstrated 
increased left ventricular wall thickness (septal wall thickness of 28 mm, posterior wall thickness of 20 mm). 
Diastolic dysfunction was noted on transmitral flow patterns and tissue Doppler imaging. The patient was found 
to have low plasma α-Gal A activity. A previously reported H46R missense mutation was detected in his α -Gal 
A gene and the patient was subsequently diagnosed with Fabry disease. (Korean Circ J 2009;39:335-339) 
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Introduction 
 
Fabry disease is a rare X-linked disorder caused by mu-
tations in the GLA gene encoding the lysosomal enzyme 
α-galactosidase A (α-Gal A). It results in a failure to 
catabolize lipids containing α -D-galactosyl moieties and 
subsequent progressive intracellular accumulation of gly-
cosphingolipids in various tissues, including skin, kid-
neys, vascular endothelium, ganglion cells of the peri-
pheral nervous system, and heart. The disorder is caused 
by mutations in the α-Gal A gene located in the X ch-
romosomal region Xq22.
1) Cardiac involvement is cha-
racterized by progressive left ventricular hypertrophy (LVH) 
that mimics the morphologic and clinical features of hy-
pertrophic cardiomyopathy (HCM), which is an inherited 
autosomal dominant disease that is caused by mutations 
in sarcomeric genes.
2)3) Since it has been reported that 
enzyme replacement therapy (ERT) is effective in reduc-
ing and clearing glycosphingolipid accumulation with 
subsequent improvement in cardiac function, early reco-
gnition of Fabry disease has become increasingly rele-
vant.
4)5) 
Here we report a case of Fabry disease which was first 
suspected based upon echocardiographic findings of LVH. 
 
Case 
 
A 44-year-old man with no history of hypertension or 
diabetes mellitus was admitted with sudden onset palpi-
tations of 2 hours duration. He had been diagnosed with 
end-stage renal disease (ESRD) of unknown etiology at 
age 33 followed by renal transplantation at age 35. Since 
that time, he had been treated with oral immunosuppre-
ssive agents, including prednisolone (5 mg daily), myco-
phenolate mofetil (1,000 mg, bid) and cyclosporine (150 
mg, bid). 
Vital signs upon arrival included a blood pressure of 
150/90 mmHg and a regular rapid pulse rate of 150 bpm. 
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The initial electrocardiogram (ECG) revealed a narrow 
QRS tachycardia of approximately 150 bpm with absent 
P waves (Fig. 1A). The patient was diagnosed with re-
entrant paroxysmal supraventricular tachycardia (PSVT) 
and was treated with intravenous adenosine. Following 
normalization of rhythm, the ECG showed LVH with a 
strain pattern, ST-T changes in leads II, V3, and V4, 
and a short PR interval (Fig. 1B). Chest radiography 
demonstrated mild cardiomegaly (Fig. 2). Laboratory stu-
dies revealed that hemoglobin was 13.3 g/dL, creatinine 
1.7 mg/dL, BUN 27 mg/dL, sodium 134 mEq/L, and 
potassium 4.1 mEq/L. On hospital day two, transtho-
racic echocardiography revealed severe concentric LVH 
(septum 28 mm, posterior wall 20 mm) without left 
ventricular outflow tract obstruction, mimicking non-
obstructive HCM (Fig. 3). Systolic left ventricular func-
tion was preserved but diastolic dysfunction was present. 
Pulsed-wave Doppler recording of mitral inflow revealed 
a phase resembling a normal diastolic filling pattern, with 
an E/A ratio of 1.6 (Fig. 4A). The mitral annulus velo-
city was obtained from the septal side of the mitral an-
A  B 
Fig. 3. 2-D echocardiography. Severe concentric left ventricular hypertrophy is shown in a parasternal long-axis view (A) and four-chamber
view (B). 
A 
B 
Fig. 1. Electrocardiography (ECG). The initial ECG (A) showed 
a narrow QRS tachycardia with absent P waves. After chemical
conversion, the ECG (B) showed left ventricular hypertrophy with
a strain pattern, ST-T changes in leads II, V3, and V4 and a short
PR interval. 
Fig. 2. Chest radiography. Chest radiography revealed mild car-
diomegaly.  
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nulus using Doppler tissue imaging to distinguish a true 
normal from a pseudonormal pattern (Fig. 4B). The 
early diastolic tissue Doppler velocity (Ea) and the E/Ea 
index were 0.5 cm/s and 22, respectively, indicating in-
creased LV filling pressure and a pseudonormal pattern. 
Since infiltrative diseases could not be ruled out based 
on clinical and echocardiographic findings, a careful his-
tory was obtained, revealing chronic hypohidrosis and 
heat intolerance. Fabry cardiomyopathy was thus suspect-
ed due to its typical history of early onset ESRD and 
renal transplantation prior to 40 years of age as well as 
hypohidrosis and heat intolerance. This diagnosis was 
confirmed by demonstration of a low plasma α-Gal A 
activity of 0.17 nmoles/hr/mL (normal mean, 8.5±2.4 
nmol/hr/mL). A His46Arg missense mutation in the 
α-Gal A gene, which resulted in the substitution of ar-
ginine for histidine, was subsequently identified from 
lymphocyte DNA (Fig. 5). A transplant renal biopsy was 
performed because chronic renal allograft rejection was 
suspected given the increased serum creatinine level and 
high resistive index of the transplanted kidney; however, 
the biopsy was unremarkable. Enzyme replacement the-
rapy with recombinant  α -Gal A was started on an out-
patient basis. 
 
Discussion 
 
Hundreds of inborn errors of metabolism have been 
reported and have been classified according to the type 
of metabolism involved. Lysosomal storage disorders, one 
of the major categories of inborn errors of metabolism 
caused by a deficiency of specific lysosomal enzymes, are 
generally classified according to the involved substrates 
as follows: sphingolipidoses, glycoproteinoses, mucolipi-
doses, mucopolysaccharidoses (MPSs), and many others. 
Cardiac disease is particularly prominent in lysosomal 
glycogen storage diseases (Pompe and Danon disease), 
MPSs and in glycosphingolipidoses (Fabry disease). Am-
ong lysosomal storage disorders, enzyme replacement 
therapy for the treatment of Gaucher disease, Pompe 
disease, Fabry disease and MPS I, II and VI has been 
approved in the United States.
6) 
Fabry disease is an X-linked recessive inborn error of 
glycosphingolipid catabolism due to deficient or absent 
activity of the lysosomal enzyme, a-Gal A. Cardiac invo-
A  B 
Fig. 4. Pulse-waved Doppler echocardiography (A) and tissue Doppler echocardiography (B). Decreased mitral annulus velocities and 
increased E/Ea ratio are seen, suggesting a pseudonormal pattern. 
Fig. 5. DNA analysis. Sequent analysis of polymerase chain re-
action (PCR)-amplified genomic DNA showing a hemizygous
single nucleotide transition (C137A>G) leading to a missense
mutation with arginine substituting for a histidine at residue 46. 
PCR-Sequence analysis 
Normal 
Patient 
c.137A>G (p.His46Arg)  
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lvement, consisting of progressive deposition of globo-
triaosylceramide (Gb3) in myocardial cells leading to LVH, 
is the most frequent cause of death.
1) Among patients 
with late-onset HCM, Fabry cardiomyopathy was diag-
nosed in up to 6% of men and up to 12% of women.
7)8) 
Cardiac accumulation of Gb3 leads to thickening of the 
cardiac wall and may cause mitral valve prolapse, arrhy-
thmia, heart attack, heart failure and stroke. Rarely, the 
heart may be the only organ involved in the so-called 
“cardiac variant,” wherein patients present with a mild, 
late-onset disorder limited to the heart.
9)10) 
Here we report a case of Fabry cardiomyopathy with 
early onset ESRD and renal transplantation. To our kn-
owledge, this is the first report of Fabry cardiomyopathy 
in Korea. The patient’s clinical and echocardiographic 
findings were suggestive of an infiltrative disease as well 
as HCM; however, HCM was thought to be more likely 
than infiltrative cardiomyopathy in which electrocardio-
graphy commonly exhibits a low voltage.
11) In addition, 
the patient had typical manifestations of Fabry disease, 
including hypohidrosis and heat intolerance, which were 
eventually diagnosed both biochemically and genetically. 
Mild left ventricular diastolic dysfunction is commonly 
present in the early stages of the disease; however, in ad-
vanced stages, systolic and severe diastolic dysfunction 
are present.
12-14) In our patient, transthoracic echocar-
diography revealed concentric LVH and stage 2 diastolic 
dysfunction. Upon initial presentation, the chief com-
plaint was palpitations with an ECG indicative of PSVT. 
The prevalence of reported persistent atrial fibrillation, 
paroxysmal atrial fibrillation, and nonsustained ventri-
cular tachycardia in Fabry disease are 3.9%, 13.3% and 
8.3%, repectively.
15) Following chemical conversion, the 
ECG revealed LVH with a strain pattern, ST-T changes 
in leads II, V3, and V4 and a short PR interval, which 
are all electrocardiographic findings common in most 
adult patients with Fabry disease. The short PR interval 
may have been the result of accelerated AV conduction 
rather than the presence of an accessory pathway.
16) 
Percutaneous biopsy of the transplanted kidney was 
performed to rule out chronic rejection. The findings 
on renal biopsy were normal, indicating that there was 
no evidence of recurrent Fabry disease in the graft. The 
risk of recurrence following renal transplantation has 
been reported to be less than 5%.
17) Both short- and long-
term outcomes with kidney transplantation in ESRD 
patients with Fabry disease are reported to be good and 
comparable to those of kidney transplant recipients who 
developed ESRD from other causes.
18) 
Following discharge, our patient began enzyme repla-
cement therapy with Fabrazyme (Agalsidase-beta). Two 
recombinant enzyme preparations of Agalsidase-alpha 
and Agalsidase-beta are now available for the treatment 
of Fabry disease. Several studies have reported the clea-
rance of microvascular endothelial deposits of globotriao-
sylceramide from the kidneys, heart and skin with sub-
sequent improvement in neurological, renal and cardiac 
manifestations of the disease as well as in quality of li-
fe.
3)4)19)20) Therefore, early diagnosis is imperative for the 
modification of these manifestations and the disease co-
urse with enzyme replacement therapy. 
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